Abivax(US:ABVX) Ge Long Hui·2025-12-10 14:58Core Viewpoint - French biotechnology company Abivax (ABVX.US) saw its stock price surge over 10% to $135.65, reaching an all-time high amid speculation that Eli Lilly may be interested in acquiring the company [1] Group 1: Market Reactions - The stock price increase reflects market optimism regarding potential acquisition interest from Eli Lilly [1] - Eli Lilly has not commented on the acquisition rumors, stating that it does not provide comments on business development activities [1] Group 2: Analyst Ratings - LifeSci Capital has maintained a "Buy" rating on Abivax, setting a target price of $170 [1] Group 3: Clinical Trial Results - Abivax reported positive results from a Phase 3 clinical trial of obefazimod for the treatment of ulcerative colitis in July [1]